The present invention relates to a Lyme disease vaccine, a genetic construct, recombinant protein, method for genetic construct design, method for vaccine delivery, method for recombinant proteins delivery, use of recombinant proteins in the production of Lyme disease vaccine. In particular, the method concerns the use of TROSPA and TROSPA- Salp15 recombinant proteins derived from castor bean tick (Ixodes riccinus) as a component of Lyme disease vaccine for animals. The antibodies present in blood of an immunized vertebrate directed against the TROSPA proteins considerably reduce the chance of infecting new ticks by blocking or hindering the interaction of TROSPA protein with OspA protein of Borrelia burgdorferi sensu lato. The interaction is crucial in the process of the spirochete entering a tick. The antibodies directed against the TROSPA- Salp15 protein protect vertebrates from infection on the stage of Borellia diffusion by destroying their protective coating formed at the surface as a result of the interaction between the Salp15 tick protein and OspC spirochete protein. The vaccine based on TROSPA tick proteins and TROSPA-Salp15 proteins may be used independently or together with the OspA recombinant proteins and OspC protein of Borrelia burgdorferi sensu lato.La présente invention concerne un vaccin contre la maladie de Lyme, une construction génétique, une protéine recombinante, un procédé de conception de construction génétique, un procédé dadministration de vaccin, un procédé dadministration de protéines recombinantes, lutilisation de protéines recombinantes dans la production dun vaccin contre la maladie de Lyme. En particulier, le procédé comprend lutilisation des protéines recombinantes TROSPA et TROSPA- Salpl 5 dérivées de la tique du mouton (Ixodes riccinus) comme composante dun vaccin contre la maladie de Lyme pour animaux. Les anticorps présents dans le sang dun vertébré immunisé dirigés contre les protéines TROSPA réduisent considérablement le risq
